MRK
$141.82+0.86%
as of close, Oct 27, 2026
☾ AH $141.82 +0.86%
MRK — Merck & Co. Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDDDDDDDDDDDDDDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDEDED
60.070.080.090.0100.0110.0120.0130.0140.0150.00100.0M200.0M$141.82—20162019202120242026
2026-10-27
Price$141.82
MA20$133.89
MA50$115.32
Vol49.6M
Key stats#
Price data
- Price
- $141.82
- YTD price return
- +34.73%
- YTD total return
- +37.51%
- Next earnings
- Oct 29, 2026 · Before open
- Market cap
- 349.9B
- Enterprise value
- 397.9B
- Shares outstanding
- 2.5B
- 52W low
- $82.01
- 52W high
- $156.92
- From 52W high
- -9.62%
- From 52W low
- +72.93%
- 52W range
- 80%
- Beta
- 0.19
Volume
- Rel volume
- 0.87×
- 30D volume
- 10.4M
- 30D $ vol
- 1.5B
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$30.0M
- Insider net 1Y
- −$70.7M
Form 4 transactions by trade date, as filed; latest on file 2026-08-13.
Fundamentals
- Sales (ttm)
- 66.6B
- Sales/share
- $26.98
- EPS (ttm)
- $1.28
- FCF (ttm)
- 16.1B
- FCF/share
- $6.51
- Book value/share
- $17.00
- Net margin
- 4.77%
- ROE
- 7.57%
- ROA
- 2.44%
- Debt / equity
- 1.22×
- Current ratio
- 1.32
Growth (CAGR, ttm) · 10Y
- Sales
- +4.65%+4.51%+8.68%+5.56%
- Net income
- -80.68%+0.66%-10.65%-4.70%
- FCF
- +9.12%+14.05%+17.76%+4.99%
- Shares
- -1.23%-0.93%-0.51%-1.13%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -80.30%+1.47%-10.23%-3.51%
- Sales/share
- +5.94%+5.50%+9.24%+6.76%
- FCF/share
- +10.47%+15.12%+18.34%+6.20%
- Book value/share
- -13.36%+3.68%+5.26%+0.81%
- Dividend/share
- +5.00%+5.27%+5.59%+6.27%
- Price
- +61.21%+11.31%+11.71%+9.34%
- Total return
- +65.95%+14.76%+15.18%+12.73%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 110.9×
- Fwd P/E
- 15.7×
- P/S (ttm)
- 5.3×
- P/B (mrq)
- 8.3×
- P/FCF (ttm)
- 21.8×
- EV/EBITDA (fy)
- 29.0×
- EV/Sales (ttm)
- 6.0×
- FCF yield (ttm)
- 4.59%
- Dividend yield (fwd)
- 2.40%
- Dividend yield (ttm)
- 2.40%
- Dividend/share (fwd)
- $3.40
- Buyback yield (realized, 1y)
- 1.23%
- Shareholder yield (realized, 1y)
- 5.42%
- Buyback yield (cash, ttm)
- 1.20%
- Shareholder yield (cash, ttm)
- 3.57%
Vs own 10Y history
- P/E
- 91st
- P/S
- 90th
- P/B
- 96th
- P/FCF
- 47th
Bar = where today’s multiple sits in MRK’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-27#
1D
+0.86%
5D
-4.37%
1M
-4.68%
3M
+8.46%
YTD
+34.73%
1Y
+61.16%
5Y
+73.93%
Recent filings#
- Oct 138-K · Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
- Aug 13Insider sale · Guindo Chirfi (EVP, Access, Policy & Comms) sold 25,000 shares for $3.3M on 2 days since Aug 6
- Aug 12Insider sale · Zachary Jennifer (EVP, General Counsel) sold 80,315 shares for $10.7M at $133.46
- Aug 12Insider sale · DeLuca Richard R. (EVP&Pres, Merck Animal Heallth) sold 51,370 shares for $6.7M on 4 days since Aug 6
- Aug 5Insider sale · Williams David Michael (EVP,Chief Info&Digital Officer) sold 52,847 shares for $6.8M at $128.77
Financial statements
Open full MRK financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +8.32% | +0.22% |
| JNJ | Johnson & Johnson | -0.92% | +0.91% |
| ABBV | AbbVie Inc. | +8.34% | -0.12% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +8.98% | -0.08% |
| NVS | Novartis AG | +7.84% | +1.98% |
| TMO | Thermo Fisher Scientific Inc. | +2.67% | +1.19% |
| AMGN | Amgen Inc. | +8.04% | +0.75% |
| GILD | Gilead Sciences Inc. | +5.40% | +0.25% |
